Isotechnika Cleared by FDA to Commence Phase 3 Voclosporin Trial Equities.com The primary endpoint of the trial will be defined as non-inferiority in biopsy proven acute rejection, or BPAR, episodes with patients receiving voclosporin for six months as compared to tacrolimus. A key secondary endpoint will be the incidence of ... |
